New strategies in drug development focusing on the anti-protease-protease balance in alpha-1 antitrypsin deficiency

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2010, Pages 314-329

  Reeves, Emer P ^a   Cosgrove, Sonya ^a   Bergin, David A ^a   Greene, Catherine M ^a   McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Alpha 1 antitrypsin; Alpha 1 antitrypsin deficiency; Gene therapy; Protease imbalance; Replacement therapy

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; DEPELESTAT; ELAFIN; ELASTASE INHIBITOR; FR 134043; MIDESTEINE; PLACEBO; POLYMER; PREDNISOLONE; PROTEIN PRECURSOR; PROTEINASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SIVELESTAT; TRAPPIN 2; UNCLASSIFIED DRUG; ZD 0892;

ALLELE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BINDING AFFINITY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPLACEMENT; GENE MUTATION; GENE THERAPY; HOST RESISTANCE; HUMAN; INFLAMMATION; NONHUMAN; PANNICULITIS; PATHOPHYSIOLOGY; POLYMERIZATION; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN TARGETING; REVIEW; TRANSGENICS; VASCULITIS;

EID: 79952753335     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871523011009040314     Document Type: Review

References (211)

1. Mason, D.Y.; Cramer, E.M.; Masse, J.M.; Crystal, R.; Bassot, J.M.; Breton-Gorius, J. Alpha 1-antitrypsin is present within the primary granules of human polymorphonuclear leukocytes. Am. J. Pathol., 1991, 139(3), 623-628.
2. Carroll, T.P.; Greene, C.M.; O'Connor, C.A.; Nolan, A.M.; O'Neill, S.J.; McElvaney, N.G. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J. Immunol., 2010, 184(8), 4538-4546.
3. Carlson, J.A.; Rogers, B.B.; Sifers, R.N.; Hawkins, H.K.; Finegold, M.J.; Woo, S.L. Multiple tissues express alpha 1-antitrypsin in transgenic mice and man. J. Clin. Invest., 1988, 82(1), 26-36.
4. Molmenti, E.P.; Perlmutter, D.H.; Rubin, D.C. Cell-specific expression of alpha 1-antitrypsin in human intestinal epithelium. J. Clin. Invest., 1993, 92(4), 2022-2034.
5. Pace, C.N. Conformational stability of globular proteins. Trends Biochem. Sci., 1990, 15(1), 14-17.
6. Elliott, P.R.; Lomas, D.A.; Carrell, R.W.; Abrahams, J.P. Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat. Struct. Biol., 1996, 3(8), 676-681.
7. Elliott, P.R.; Pei, X.Y.; Dafforn, T.R.; Lomas, D.A. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci., 2000, 9(7), 1274-1281.
8. Johnson, D.; Travis, J. Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor. J. Biol. Chem., 1978, 253(20), 7142-7144.
9. Lomas, D.A.; Elliott, P.R.; Carrell, R.W. Commercial plasma al-pha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component. Eur. Respir. J., 1997, 10(3), 672-675.
10. Lomas, D.A.; Elliott, P.R.; Chang, W.S.; Wardell, M.R.; Carrell, R.W. Preparation and characterization of latent alpha 1-antitrypsin. J. Biol. Chem., 1995, 270(10), 5282-5288.
11. Janciauskiene, S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Bio-chim. Biophys. Acta., 2001, 1535(3), 221-235.
12. Banda, M.J.; Rice, A.G.; Griffin, G.L.; Senior, R.M. The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant. J. Exp. Med., 1988, 167(5), 1608-1615.
13. Taggart, C.; Cervantes-Laurean, D.; Kim, G.; McElvaney, N.G.; Wehr, N.; Moss, J.; Levine, R. L. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J. Biol. Chem., 2000, 275(35), 27258-27265.
14. Moraga, F.; Janciauskiene, S. Activation of primary human mono-cytes by the oxidized form of alpha1-antitrypsin. J. Biol. Chem., 2000, 275(11), 7693-7700.
15. de Serres, F.J. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest, 2002, 122(5), 1818-1829.
16. Cox, D.W.; Markovic, V.D.; Teshima, I.E. Genes for immuno-globulin heavy chains and for alpha 1-antitrypsin are localized to specific regions of chromosome 14q. Nature, 1982, 297(5865), 428-430.
17. Lai, E.C.; Kao, F.T.; Law, M.L.; Woo, S.L. Assignment of the alpha 1-antitrypsin gene and a sequence-related gene to human chromosome 14 by molecular hybridization. Am. J. Hum. Genet., 1983, 35(3), 385-292.
18. DeMeo, D.L.; Silverman, E.K. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax, 2004, 59(3), 259-264.
19. Crystal, R.G. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J. Clin. Invest., 1990, 85(5), 1343-1352.
20. Curiel, D.T.; Chytil, A.; Courtney, M.; Crystal, R.G. Serum alpha 1-antitrypsin deficiency associated with the common S-type (Glu264----Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion. J. Biol. Chem., 1989, 264(18), 10477-10486.
21. Lomas, D.A.; Evans, D.L.; Finch, J.T.; Carrell, R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature, 1992, 357(6379), 605-607.
22. Brantly, M.; Nukiwa, T.; Crystal, R.G. Molecular basis of alpha-1-antitrypsin deficiency. Am. J. Med., 1988, 84(6A), 13-31.
23. Brantly, M.; Courtney, M.; Crystal, R.G. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. Science, 1988, 242(4886), 1700-1702.
24. Fregonese, L.; Stolk, J.; Frants, R.R.; Veldhuisen, B. Alpha-1 anti-trypsin Null mutations and severity of emphysema. Respir. Med., 2008, 102(6), 876-884.
25. Mahadeva, R.; Lomas, D.A. Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax, 1998, 53(6), 501-5.
26. Dafforn, T.R.; Mahadeva, R.; Elliott, P.R.; Sivasothy, P.; Lomas, D.A. A kinetic mechanism for the polymerization of alpha1-antitrypsin. J. Biol. Chem., 1999, 274(14), 9548-9555.
27. Gishen, P.; Saunders, A.J.; Tobin, M.J.; Hutchison, D.C. Alpha 1-antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. Clin. Radiol., 1982, 33(4), 371-377.
28. Lieberman, J.; Winter, B.; Sastre, A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest, 1986, 89(3), 370-373.
29. Larsson, C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med. Scand., 1978, 204(5), 345-351.
30. Parr, D.G.; Guest, P.G.; Reynolds, J.H.; Dowson, L.J.; Stockley, R.A. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am. J. Respir. Crit. Care. Med., 2007, 176(12), 1215-1221.
31. Perlmutter, D.H. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J. Clin. Invest., 2002, 110(11), 1579-1583.
32. Eriksson, S.; Carlson, J.; Velez, R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N. Engl. J. Med., 1986, 314(12), 736-739.
33. Laurell, C.B.; Sveger, T. Mass screening of newborn Swedish infants for alpha antitrypsin deficiency. Am. J. Hum. Genet., 1975, 27(2), 213-217.
34. Sveger, T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N. Engl. J. Med., 1976, 294(24), 1316-1321.
35. Hussain, M.; Mieli-Vergani, G.; Mowat, A.P. Alpha 1-antitrypsin deficiency and liver disease: clinical presentation, diagnosis and treatment. J. Inherit. Metab. Dis., 1991, 14(4), 497-511.
36. American Thoracic Society/European Respiratory Society state ment: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am. J. Respir. Crit. Care Med., 2003, 168(7), 818-900.
37. Warter, J.; Storck, D.; Grosshans, E.; Metais, P.; Kuntz, J.L.; Klumpp, T. [Weber-Christian syndrome associated with an alpha-1 antitrypsin deficiency. Familial investigation]. Ann. Med. Interne. (Paris)., 1972, 123(10), 877-882.
38. Crystal, R.G.; Weibel, E.R.; Barnes, P.J. The Lung: Scientific Foundations: Raven Press, Inc. New York, 1997.
39. Fernandez-Torres, R.; Garcia-Silva, J.; Robles, O.; Otero, A.; Vazquez, M.A.; Fonseca, E. Alfa-1-antitrypsin deficiency pannicu-litis acquired after liver transplant and successfully treated with re-transplant. J. Am. Acad. Dermatol., 2009, 60(4), 715-716.
40. Chowdhury, M.M.; Williams, E.J.; Morris, J.S.; Ferguson, B.J.; McGregor, A.D.; Hedges, A.R.; Stamatakis, J. D.; Pope, F. M. Severe panniculitis caused by homozygous ZZ alpha1-antitrypsin deficiency treated successfully with human purified enzyme (Pro-lastin). Br. J. Dermatol., 2002, 147(6), 1258-1261.
41. Gross, B.; Grebe, M.; Wencker, M.; Stoller, J.K.; Bjursten, L.M.; Janciauskiene, S. New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology, 2009, 218(4), 370-375.
42. Colp, C.; Pappas, J.; Moran, D.; Lieberman, J. Variants of alpha 1-antitrypsin in Puerto Rican children with asthma. Chest, 1993, 103(3), 812-815.
43. Cox, D.W. Alpha 1-antitrypsin: a guardian of vascular tissue. Mayo Clin. Proc., 1994, 69(11), 1123-1124.
44. Hirche, T.O.; Benabid, R.; Deslee, G.; Gangloff, S.; Achilefu, S.; Guenounou, M.; Lebargy, F.; Hancock, R. E.; Belaaouaj, A. Neu-trophil elastase mediates innate host protection against Pseudo-monas aeruginosa. J. Immunol., 2008, 181(7), 4945-4954.
45. Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN, Shapiro, S.D. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat. Med., 1998, 4(5), 615-618.
46. Sorensen, O.E.; Follin, P.; Johnsen, A.H.; Calafat, J.; Tjabringa, G.S.; Hiemstra, P.S.; Borregaard, N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood, 2001, 97(12), 3951-3959.
47. Griffin, S.; Taggart, C.C.; Greene, C.M.; O'Neill, S.; McElvaney, N.G. Neutrophil elastase up-regulates human beta-defensin-2 expression in human bronchial epithelial cells. FEBS Lett., 2003, 546(2-3), 233-236.
48. Rouhani, F.; Paone, G.; Smith, N.K.; Krein, P.; Barnes, P.; Brantly, M.L. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with alpha(1)-antitrypsin deficiency. Chest, 2000, 117(5), 250S-251S.
49. Campbell, E.J.; Campbell, M.A.; Owen, C.A. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J. Immunol., 2000, 165(6), 3366-3374.
50. Geraghty, P.; Rogan, M.P.; Greene, C.M.; Boxio, R.M.; Poiriert, T.; O'Mahony, M.; Belaaouaj, A.; O'Neill, S. J.; Taggart, C. C.; McElvaney, N. G. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J. Immunol. 2007, 178(9), 5871-5878.
51. Elkington, P.T.; O'Kane, C.M.; Friedland, J.S. The paradox of matrix metalloproteinases in infectious disease. Clin. Exp. Immunol. 2005, 142(1), 12-20.
52. Ferry, G.; Lonchampt, M.; Pennel, L.; de Nanteuil, G.; Canet, E.; Tucker, G.C. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett., 1997, 402(2-3), 111-115.
53. Van den Steen, P.E.; Proost, P.; Wuyts, A.; Van Damme, J.; Opde-nakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood, 2000, 96(8), 2673-2681.
54. Heppner, K.J.; Matrisian, L.M.; Jensen, R.A.; Rodgers, W.H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol., 1996, 149(1), 273-282.
55. Jackson, P.L.; Xu, X.; Wilson, L.; Weathington, N.M.; Clancy, J.P.; Blalock, J.E.; Gaggar, A. Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibro-sis proteolytic dysfunction. Mol. Med., 2010, 16(5-6), 159-166.
56. Bergin, D.A.; Greene, C.M.; Sterchi, E.E.; Kenna, C.; Geraghty, P.; Taggart, C.C.; O'Neill, S. J.; McElvaney, N. G. Activation of EGFR by a novel metalloprotease pathway. J. Biol. Chem., 2008, 284(14), 9624.
57. Okada, Y.; Nakanishi, I. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 ('gelatinase') by human neutrophil elastase and cathepsin G. FEBS Lett., 1989, 249(2), 353-356.
58. Shamamian, P.; Schwartz, J.D.; Pocock, B.J.; Monea, S.; Whiting, D.; Marcus, S.G.; Mignatti, P. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J. Cell Physiol., 2001, 189(2), 197-206.
59. Dalet-Fumeron, V.; Guinec, N.; Pagano, M. In vitro activation of pro-cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator. FEBS Lett., 1993, 332(3), 251-254.
60. Kelly, E.; Greene, C.M.; Carroll, T.P.; McElvaney, N.G.; O'Neill, S.J. Alpha-1 antitrypsin deficiency. Respir. Med., 2010, 104(6), 763-772.
61. Gaggar, A.; Jackson, P.L.; Noerager, B.D.; O'Reilly, P.J.; McQuaid, D.B.; Rowe, S.M.; Clancy, J. P.; Blalock, J. E. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J. Immunol., 2008, 180(8), 5662-5669.
62. Lin, M.; Jackson, P.; Tester, A.M.; Diaconu, E.; Overall, C.M.; Blalock, J.E.; Pearlman, E. Matrix metalloproteinase-8 facilitates neutrophil migration through the corneal stromal matrix by collagen degradation and production of the chemotactic peptide Pro-Gly-Pro. Am. J. Pathol., 2008, 173(1), 144-153.
63. Abe, H.; Okajima, K.; Okabe, H.; Takatsuki, K.; Binder, B.R. Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J. Lab. Clin. Med., 1994, 123(6), 874-881.
64. Ariel, A.; Yavin, E.J.; Hershkoviz, R.; Avron, A.; Franitza, S.; Hardan, I.; Cahalon, L.; Fridkin, M.; Lider, O. IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase. J. Immunol., 1998, 161(5), 2465-72.
65. Carden, D.; Xiao, F.; Moak, C.; Willis, B.H.; Robinson-Jackson, S.; Alexander, S. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am. J. Physiol., 1998, 275(2 Pt 2), H385-392.
66. Ginzberg, H.H.; Cherapanov, V.; Dong, Q.; Cantin, A.; McCulloch, C.A.; Shannon, P.T.; Downey, G. P. Neutrophil-mediated epithelial injury during transmigration: role of elastase. Am. J. Physiol. Gas-trointest. Liver Physiol., 2001, 281(3), G705-717.
67. Berger, M.; Sorensen, R.U.; Tosi, M.F.; Dearborn, D.G.; Doring, G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J. Clin. Invest., 1989, 84(4), 1302-1313.
68. Tosi, M.F.; Zakem, H.; Berger, M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J. Clin. Invest., 1990, 86(1), 300-308.
69. Fischer, B.M.; Voynow, J.A. Neutrophil elastase induces MUC5AC gene expression in airway epithelium via a pathway in volving reactive oxygen species. Am. J. Respir. Cell. Mol. Biol., 2002, 26(4), 447-452.
70. Lundgren, J.D.; Rieves, R.D.; Mullol, J.; Logun, C.; Shelhamer, J.H. The effect of neutrophil protenase enzymes on the release of mucus from feline and human airway cultures. Respir. Med., 1994, 88(7), 511-518.
71. 2+ oscillations. Am. J. Respir. Cell. Mol. Biol., 1998, 18(1), 32-42.
72. Voynow, J.A.; Fischer, B.M.; Malarkey, D.E.; Burch, L.H.; Wong, T.; Longphre, M.; Ho, S. B.; Foster, W. M. Neutrophil elastase induces mucus cell metaplasia in mouse lung. Am. J. Physiol. Lung. Cell. Mol. Physiol., 2004, 287(6), L1293-1302.
73. Shao, M.X.; Ueki, I.F.; Nadel, J.A. Tumor necrosis factor alpha- converting enzyme mediates MUC5AC mucin expression in cul tured human airway epithelial cells. Proc. Natl. Acad. Sci., USA, 2003, 100(20), 11618-11623.
74. Fischer, B.M.; Domowicz, D.A.; Zheng, S.; Carter, J.L.; McElva-ney, N.G.; Taggart, C.; Lehmann, J. R.;Voynow, J. A.; Ghio, A. J. Neutrophil elastase increases airway epithelial nonheme iron levels. Clin. Transl. Sci., 2009, 2(5), 333-339.
75. Rogan, M.P.; Taggart, C.C.; Greene, C.M.; Murphy, P.G.; O'Neill, S.J.; McElvaney, N.G. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J. Infect. Dis., 2004, 190(7), 1245-153.
76. Taggart, C.C.; Greene, C.M.; Smith, S.G.; Levine, R.L.; McCray, P.B.Jr.; O'Neill, S.; McElvaney, N. G. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J. Immunol., 2003, 171(2), 931-937.
77. Bergsson, G.; Reeves, E.P.; McNally, P.; Chotirmall, S.H.; Greene, C.M.; Greally, P.; Murphy, P.; O'Neill, S. J.; McElvaney, N. G. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hy-pertonic saline. J. Immunol., 2009, 183(1), 543-551.
78. Gaggar, A.; Li, Y.; Weathington, N.; Winkler, M.; Kong, M.; Jackson, P.; Blalock, J. E.; Clancy, J. P. Matrix metalloprotease-9 dys-regulation in lower airway secretions of cystic fibrosis patients. Am. J. Physiol. Lung. Cell. Mol. Physiol., 2007, 293(1), L96-L104.
79. Zhu, Y.K.; Liu, X.D.; Skold, C.M.; Umino, T.; Wang, H.J.; Spurzem, J.R.; Kohyama, T.; Ertl, R. F.; Rennard, S. I. Synergistic neutrophil elastase-cytokine interaction degrades collagen in three-dimensional culture. Am. J. Physiol. Lung. Cell. Mol. Physiol., 2001, 281(4), L868-878.
80. Abrahamson, M.; Mason, R.W.; Hansson, H.; Buttle, D.J.; Grubb, A.; Ohlsson, K. Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactiva-tion by leucocyte elastase. Biochem. J., 1991, 273 (Pt 3), 621-626.
81. Weldon, S.; McNally, P.; McElvaney, N.G.; Elborn, J.S.; McAuley, D.F.; Wartelle, J.; Wartelle, J.; Belaaouaj, A.; Levine, R. L.; Taggart, C. C. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J. Immunol., 2009, 183(12), 48-56.
82. Guyot, N.; Butler, M.W.; McNally, P.; Weldon, S.; Greene, C.M.; Levine, R.L.; O'Neill, S. J.; Taggart, C. C.; McElvaney, N. G. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J. Biol. Chem., 2008, 283(47), 32377-32385.
83. Carpenter, S.; O'Neill, L.A. How important are Toll-like receptors for antimicrobial responses? Cell. Microbiol., 2007, 9(8), 1891-1901.
84. Devaney, J.M.; Greene, C.M.; Taggart, C.C.; Carroll, T.P.; O'Neill, S.J.; McElvaney, N.G. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett., 2003, 544(1-3), 129-132.
85. Walsh, D.E.; Greene, C.M.; Carroll, T.P.; Taggart, C.C.; Gallagher, P.M.; O'Neill, S.J.; McElvaney, N. G. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J. Biol. Chem., 2001, 276(38), 35494-35499.
86. Kuwahara, I.; Lillehoj, E.P.; Lu, W.; Singh, I.S.; Isohama, Y.; Miyata, T.; Kim, K. C. Neutrophil elastase induces IL-8 gene transcription and protein release through p38/NF-{kappa}B activation via EGFR transactivation in a lung epithelial cell line. Am. J. Physiol. Lung. Cell. Mol. Physiol., 2006, 291(3), L407-416.
87. Lemjabbar, H.; Basbaum, C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat. Med., 2002, 8(1), 41-46.
88. Koff, J.L.; Shao, M.X.; Ueki, I.F.; Nadel, J.A. Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am. J. Physiol. Lung Cell. Mol. Physiol., 2008, 294(6), L1068-1075.
89. Shao, M.X.; Nadel, J.A. Dual oxidase 1-dependent MUC5AC mucin expression in cultured human airway epithelial cells. Proc. Natl. Acad. Sci. USA, 2005, 102(3), 767-772.
90. Nemoto, E.; Sugawara, S.; Tada, H.; Takada, H.; Shimauchi, H.; Horiuchi, H. Cleavage of CD14 on human gingival fibroblasts co-cultured with activated neutrophils is mediated by human leukocyte elastase resulting in down-regulation of lipopolysaccharide-induced IL-8 production. J. Immunol., 2000, 165(10), 5807-5813.
91. Vandivier, R.W.; Fadok, V.A.; Hoffmann, P.R.; Bratton, D.L.; Penvari, C.; Brown, K.K.; Brain, J. D.; Accurso, F. J.; Henson, P. M. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J. Clin. Invest., 2002, 109(5), 661-670.
92. Ostrowska, E.; Sokolova, E.; Reiser, G. PAR-2 activation and LPS synergistically enhance inflammatory signaling in airway epithelial cells by raising PAR expression level and interleukin-8 release. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 293(5), L1208-218.
93. Ramachandran, R.; Hollenberg, M.D. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol., 2008, 153(1), S263-282.
94. Gartner, J.C. Jr.; Zitelli, B.J.; Malatack, J.J.; Shaw, B.W.; Iwatsuki, S.; Starzl, T.E. Orthotopic liver transplantation in children: two-year experience with 47 patients. Pediatrics, 1984, 74(1), 140-145.
95. Hood, J.M.; Koep, L.J.; Peters, R.L.; Schroter, G.P.; Weil, R. 3rd.; Redeker, A.G.; Starzl, T. E. Liver transplantation for advanced liver disease with alpha-1-antitrypsin deficiency. N. Engl. J. Med., 1980, 302(5), 272-275.
96. Turino, G.M.; Barker, A.F.; Brantly, M.L.; Cohen, A.B.; Connelly, R.P.; Crystal, R.G.; Eden, E.; Schluchter, M. D.; Stoller, J. K. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. Am. J. Respir. Crit. Care. Med., 1996, 154(6 Pt 1), 1718-1725.
97. Jones, E.A.; Vergalla, J.; Steer, C.J.; Bradley-Moore, P.R.; Vier-ling, J.M. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin. Sci. Mol. Med., 1978, 55(2), 139-148.
98. Abboud, R.T.; Ford, G.T.; Chapman, K.R. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can. Respir. J., 2001, 8(2), 81-88.
99. Mordwinkin, N.M.; Louie, S.G. Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. Expert. Opin. Pharmacother., 2007, 8(15), 2609-2614.
100. Stocks, J.M.; Brantly, M.; Pollock, D.; Barker, A.; Kueppers, F.; Strange, C.; Strange, C.; Donohue, J. F.; Sandhaus, R. Multi-center study: the biochemical efficacy, safety and tolerability of a new al-pha1-proteinase inhibitor, Zemaira. COPD, 2006, 3(1), 17-23.
101. Wewers, M.D.; Casolaro, M.A.; Sellers, S.E.; Swayze, S.C.; McPhaul, K.M.; Wittes, J.T.; Crystal, R. G. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med., 1987, 316(17), 1055-1062.
102. Russi, E.W. Alpha-1 antitrypsin: now available, but do we need it? Swiss Med. Wkly., 2008, 138(13-14), 191-196.
103. Seersholm, N.; Wencker, M.; Banik, N.; Viskum, K.; Dirksen, A.; Kok-Jensen, A.; Konietzko, N. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur. Respir. J., 1997, 10(10), 2260-2263.
104. Wencker, M.; Fuhrmann, B.; Banik, N.; Konietzko, N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest, 2001, 119(3), 737-744.
105. Campos, M.A.; Alazemi, S.; Zhang, G.; Wanner, A.; Salathe, M.; Baier, H.; Sandhaus, R. A. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Respir. Med., 2009, 103(10), 1532-1539.
106. Lieberman, J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest, 2000, 118(5), 1480-1485.
107. Dirksen, A.; Dijkman, J.H.; Madsen, F.; Stoel, B.; Hutchison, D.C.; Ulrik, C.S.; Skovgaard, L. T.; Kok-Jensen, A.; Rudolphus, A.; Seer-sholm, N.; Vrooman, H. A.; Reiber, J. H.; Hansen, N. C.; Heck-scher, T.; Viskum, K.; Stolk, J.; A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care. Med., 1999, 160(5 Pt 1), 1468-1472.
108. Dirksen, A.; Piitulainen, E.; Parr, D.G.; Deng, C.; Wencker, M.; Shaker, S.B.; Stockley, R. A. Exploring the role of CT densitome-try: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur. Respir. J., 2009, 33(6), 1345-1353.
109. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of al-pha1-antitrypsin. Am. J. Respir. Crit. Care Med., 1998, 158(1), 49-59.
110. Gottlieb, D.J.; Luisetti, M.; Stone, P.J.; Allegra, L.; Cantey-Kiser, J.M.; Grassi, C.; Snider, G. L. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group. Am. J. Respir. Crit. Care Med., 2000, 162(6), 2069-2072.
111. Tonelli, A.R.; Rouhani, F.; Li, N.; Schreck, P.; Brantly, M.L. Al-pha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int. J. Chron. Obstruct. Pulmon. Dis., 2009, 4, 443-452.
112. Valverde, R.; Rosales, B.; Ortiz-de Frutos, F.J.; Rodriguez-Peralto, J.L.; Ortiz-Romero, P.L. Alpha-1-antitrypsin deficiency pannicu-litis. Dermatol. Clin., 2008, 26(4), 447-451.
113. Shimanovich, I.; Mihai, S.; Oostingh, G.J.; Ilenchuk, T.T.; Brocker, E.B.; Opdenakker, G.; Zillikens, D.; Sitaru, C. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol., 2004, 204(5), 519-527.
114. Liu, Z.; Shapiro, S.D.; Zhou, X.; Twining, S.S.; Senior, R.M.; Giudice, G.J.; Fairley, J. A.; Diaz, L. A. A critical role for neutro-phil elastase in experimental bullous pemphigoid. J. Clin. Invest., 2000, 105(1), 113-123.
115. Verraes, S.; Hornebeck, W.; Polette, M.; Borradori, L.; Bernard, P. Respective contribution of neutrophil elastase and matrix metallo-proteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J. Invest. Dermatol., 2001, 117(5), 1091-1096.
116. Oikarinen, A.; Kiistala, U.; Uitto, J. Characterization of elastase-like enzymes in various blistering diseases. Acta. Derm. Venereol., 1986, 66(1),1-5.
117. Ikeda, S.; Manabe, M.; Muramatsu, T.; Takamori, K.; Ogawa, H. Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate. J. Am. Acad. Dermatol., 1988, 18(6), 1246-1252.
118. Hubbard, R.C.; McElvaney, N.G.; Sellers, S.E.; Healy, J.T.; Czer-ski, D.B.; Crystal, R.G. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J. Clin. Invest., 1989, 84(4), 1349-1354.
119. McElvaney, N.G.; Hubbard, R.C.; Birrer, P.; Chernick, M.S.; Caplan, D.B.; Frank, M.M.; Crystal, R. G. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet, 1991, 337(8738), 392-394.
120. Hartl, D.; Latzin, P.; Hordijk, P.; Marcos, V.; Rudolph, C.; Woischnik, M.; Krauss-Etschmann, S.; Koller, B.; Reinhardt, D.; Roscher, A. A.; Roos, D.; Griese, M. Cleavage of CXCR1 on neu-trophils disables bacterial killing in cystic fibrosis lung disease. Nat. Med., 2007, 13(12), 1423-1430.
121. Smith, R.M.; Traber, L.D.; Traber, D.L.; Spragg, R.G. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. J. Clin. Invest., 1989, 84(4), 1145-1154.
122. Griese, M.; Latzin, P.; Kappler, M.; Weckerle, K.; Heinzlmaier, T.; Bernhardt, T.; Hartl, D. Alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur. Respir. J., 2007, 29(2), 240-250.
123. Geraghty, P.; Rogan, M.P.; Greene, C.M.; Brantly, M.L.; O'Neill, S.J.; Taggart, C.C.; McElvaney, N. G. Alpha-1-antitrypsin aero-solised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro. Thorax, 2008, 63(7), 621-626.
124. Rose, F.; Hattar, K.; Gakisch, S.; Grimminger, F.; Olschewski, H.; Seeger, W.; Tschuschner, A.; Schermuly, R. T.; Weissmann, N.; Hanze, J.; Sibelius, U.; Ghofrani, H. A. Increased neutrophil mediator release in patients with pulmonary hypertension--suppression by inhaled iloprost. Thromb. Haemost., 2003, 90(6), 1141-1149.
125. Ilkiw, R.; Todorovich-Hunter, L.; Maruyama, K.; Shin, J.; Rabino-vitch, M. SC-39026, a serine elastase inhibitor, prevents musculari-zation of peripheral arteries, suggesting a mechanism of monocro-taline-induced pulmonary hypertension in rats. Circ. Res., 1989, 64(4), 814-225.
126. Todorovich-Hunter, L.; Dodo, H.; Ye, C.; McCready, L.; Keeley, F.W.; Rabinovitch, M. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am. Rev. Respir. Dis., 1992, 146(1), 213-223.
127. Cowan, K.N.; Heilbut, A.; Humpl, T.; Lam, C.; Ito, S.; Rabino-vitch, M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med., 2000, 6(6), 698-702.
128. Guyot, N.; Zani, M.L.; Berger, P.; Dallet-Choisy, S.; Moreau, T. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. Biol. Chem., 2005, 386(4), 391-399.
129. Alkemade, J.A.; Molhuizen, H.O.; Ponec, M.; Kempenaar, J.A.; Zeeuwen, P.L.; de Jongh, G.J.; van Vlijmen-Willems, I. M.; van Erp, P. E.; van de Kerkhof, P. C.; Schalkwijk, J. SKALP/elafin is an inducible proteinase inhibitor in human epidermal keratinocytes. J. Cell Sci., 1994, 107(Pt 8), 2335-2342.
130. van Wetering, S.; van der Linden, A.C.; van Sterkenburg, M.A.; de Boer, W.I.; Kuijpers, A.L.; Schalkwijk, J.; Hiemstra, P. S. Regula tion of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am. J. Physiol. Lung Cell Mol. Physiol., 2000, 278(1), L51-58.
131. Mihaila, A.; Tremblay, G.M. Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. Z. Naturforsch. C., 2001, 56(3-4), 291-297.
132. Sallenave, J.M.; Si, Tahar. M.; Cox, G.; Chignard, M.; Gauldie, J. Secretory leukocyte proteinase inhibitor is a major leukocyte elas-tase inhibitor in human neutrophils. J. Leukoc. Biol., 1997, 61(6), 695-702.
133. Guyot, N.; Zani, M.L.; Maurel, M.C.; Dallet-Choisy, S.; Moreau, T. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry, 2005. 44(47), 15610-15618.
134. Reid, P.T.; Marsden, M.E.; Cunningham, G.A.; Haslett, C.; Salle-nave, J.M. Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett., 1999, 457(1), 33-37.
135. Sallenave, J.M.; Shulmann, J.; Crossley, J.; Jordana, M.; Gauldie, J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol., 1994, 11(6), 733-741.
136. Simpson, A.J.; Cunningham, G.A.; Porteous, D.J.; Haslett, C.; Sallenave, J.M. Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum. Gene. Ther., 2001, 12(11), 1395-1406.
137. Butler, M.W.; Robertson, I.; Greene, C.M.; O'Neill, S.J.; Taggart, C.C.; McElvaney, N.G. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J. Biol. Chem., 2006, 281(46), 34730-34735.
138. Henriksen, P.A.; Hitt, M.; Xing, Z.; Wang, J.; Haslett, C.; Riemersma, R.A.; Webb, D. J.; Kotelevtsev, Y. V.; Sallenave, J. M. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J. Immunol., 2004, 172(7), 4535-4544.
139. Simpson, A.J.; Maxwell, A.I.; Govan, J.R.; Haslett, C.; Sallenave, J.M. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett., 1999, 452(3), 309-313.
140. Simpson, A.J.; Wallace, W.A.; Marsden, M.E.; Govan, J.R.; Porte-ous, D.J.; Haslett, C.; Sallenave, J. M. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J. Immunol., 2001, 167(3), 1778-1786.
141. Wilkinson, T.S.; Dhaliwal, K.; Hamilton, T.W.; Lipka, A.F.; Far-rell, L.; Davidson, D.J.; Duffin, R.; Morris, A. C.; Haslett, C.; Govan, J. R.; Gregory, C. D.; Sallenave, J. M.; Simpson, A. J. Trappin-2 promotes early clearance of Pseudomonas aeruginosa through CD14-dependent macrophage activation and neutrophil recruitment. Am. J. Pathol., 2009, 174(4), 1338-1346.
142. Zaidi, S.H.; You, X.M.; Ciura, S.; Husain, M.; Rabinovitch, M. Overexpression of the serine elastase inhibitor elafin protects trans-genic mice from hypoxic pulmonary hypertension. Circulation, 2002, 105(4), 516-521.
143. Nobar, S.M.; Zani, M.L.; Boudier, C.; Moreau, T.; Bieth, J.G. Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3. FEBS J., 2005, 272(22), 5883-5893.
144. Hochstrasser, K.; Reichert, R.; Schwarz, S.; Werle, E. [Isolation and characterisation of a protease inhibitor from human bronchial secretion]. Hoppe Seylers Z. Physiol. Chem., 1972, 353(2), 221-226.
145. Doumas, S.; Kolokotronis, A.; Stefanopoulos, P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect. Immun., 2005, 73(3), 1271-1274.
146. Jin, F.Y.; Nathan, C.; Radzioch, D.; Ding, A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell, 1997, 88(3), 417-426.
147. Ding, A.; Yu, H.; Yang, J.; Shi, S.; Ehrt, S. Induction of macro-phage-derived SLPI by Mycobacterium tuberculosis depends on TLR2 but not MyD88. Immunology, 2005, 116(3), 381-389.
148. Zhang, Y.; DeWitt, D.L.; McNeely, T.B.; Wahl, S.M.; Wahl, L.M. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J. Clin. Invest., 1997, 99(5), 894-900.
149. Yang, J.; Zhu, J.; Sun, D.; Ding, A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim. Biophys. Acta., 2005, 1745(3), 310-317.
150. Geraghty, P.; Greene, C.M.; O'Mahony, M.; O'Neill, S.J.; Taggart, C.C.; McElvaney, N.G. Secretory leucocyte protease inhibitor inhibits interferon-gamma-induced cathepsin S expression. J. Biol. Chem., 2007, 282(46), 33389-33395.
151. Taggart, C.C.; Cryan, S.A.; Weldon, S.; Gibbons, A.; Greene, C.M.; Kelly, E.; Low, T. B.; O'Neill S. J.; McElvaney, N. G. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J. Exp. Med., 2005, 202(12), 1659-1668.
152. Greene, C.M.; McElvaney, N.G.; O'Neill, S.J.; Taggart, C.C. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect. Immun., 2004, 72(6), 3684-3687.
153. Taggart, C.C.; Greene, C.M.; McElvaney, N.G.; O'Neill, S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J. Biol. Chem., 2002, 277(37), 33648-33653.
154. Tomee, J.F.; Hiemstra, P.S.; Heinzel-Wieland, R.; Kauffman, H.F. Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. J. Infect. Dis., 1997, 176(3), 740-747.
155. Wiedow, O.; Harder, J.; Bartels, J.; Streit, V.; Christophers, E. Antileukoprotease in human skin: an antibiotic peptide constitu-tively produced by keratinocytes. Biochem. Biophys. Res. Com-mun., 1998, 248(3), 904-909.
156. Ma, G.; Greenwell-Wild, T.; Lei, K.; Jin, W.; Swisher, J.; Harde-gen, N.; Wild, C. T.;Wahl, S. M. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med., 2004, 200(10), 1337-1346.
157. McNeely, T.B.; Shugars, D.C.; Rosendahl, M.; Tucker, C.; Eisen-berg, S.P.; Wahl, S.M. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood, 1997, 90(3), 1141-1149.
158. Vogelmeier, C.; Buhl, R.; Hoyt, R.F.; Wilson, E.; Fells, G.A.; Hubbard, R.C.; Schnebli, H. P.; Thompson, R. C.; Crystal, R. G. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J. Appl. Physiol., 1990, 69(5), 1843-1848.
159. McElvaney, N.G.; Nakamura, H.; Birrer, P.; Hebert, C.A.; Wong, W.L.; Alphonso, M.; Baker, J. B.; Catalano, M. A.; Crystal, R. G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J. Clin. Invest., 1992, 90(4), 1296-1301.
160. Birrer, P.; McElvaney, N.G.; Rudeberg, A.; Sommer, C.W.; Liechti-Gallati, S.; Kraemer, R.; Hubbard, R.; Crystal, R. G. Prote-ase-antiprotease imbalance in the lungs of children with cystic fi-brosis. Am. J. Respir. Crit. Care. Med., 1994, 150(1), 207-213.
161. Taggart, C.C.; Lowe, G.J.; Greene, C.M.; Mulgrew, A.T.; O'Neill, S.J.; Levine, R.L.; McElvaney, N. G. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J. Biol. Chem., 2001, 276(36), 33345-33352.
162. Gibbons, A.M.; McElvaney, N.G.; Taggart, C.C.; Cryan, S.A. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J. Microencapsul., 2009, 26(6), 513-522.
163. Iba, T.; Kidokoro, A.; Fukunaga, M.; Takuhiro, K.; Yoshikawa, S.; Sugimotoa, K. Pretreatment of sivelestat sodium hydrate improves the lung microcirculation and alveolar damage in lipopolysaccha-ride-induced acute lung inflammation in hamsters. Shock, 2006, 26(1), 95-98.
164. Yasui, S.; Nagai, A.; Aoshiba, K.; Ozawa, Y.; Kakuta, Y.; Konno, K. A specific neutrophil elastase inhibitor (ONO-5046.Na) attenuates LPS-induced acute lung inflammation in the hamster. Eur. Respir. J., 1995, 8(8), 1293-1299.
165. Nakatani, K.; Takeshita, S.; Tsujimoto, H.; Kawamura, Y.; Sekine, I. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J. Leukoc. Biol., 2001, 69(2), 241-7.
166. Song, J.S.; Kang, C.M.; Rhee, C.K.; Yoon, H.K.; Kim, Y.K.; Moon, H.S.; Park, S. H. Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis. Exp. Lung. Res., 2009, 35(10), 817-829.
167. Luisetti, M.; Sturani, C.; Sella, D.; Madonini, E.; Galavotti, V.; Bruno, G.; Peona, V.; Kucich, U.; Dagnino, G.; Rosenbloom, J.; Starcher, B.; Grassi, C. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Respir. J., 1996, 9(7), 1482-1486.
168. Wright, J.L.; Farmer, S.G.; Churg, A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am. J. Respir. Crit. Care Med., 2002, 166(7), 954-960.
169. Shinguh, Y.; Imai, K.; Yamazaki, A.; Inamura, N.; Shima, I.; Wa-kabayashi, A.; Higashi, Y.; Ono, T. Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor. Eur. J. Pharmacol., 1997, 337(1), 63-71.
170. Attucci, S.; Gauthier, A.; Korkmaz, B.; Delepine, P.; Martino, M.F.; Saudubray, F.; Diot, P.; Gauthier, F. EPI-hNE4, a proteoly-sis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J. Pharmacol. Exp. Ther., 2006, 318(2), 803-809.
171. Delacourt, C.; Herigault, S.; Delclaux, C.; Poncin, A.; Levame, M.; Harf, A.; Saudubray, F.; Lafuma, C. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respir. Cell. Mol. Biol., 2002, 26(3), 290-297.
172. Zani, M.L.; Baranger, K.; Guyot, N.; Dallet-Choisy, S.; Moreau, T. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Sci., 2009, 18(3), 579-594.
173. Yu, M.H.; Lee, K.N.; Kim, J. The Z type variation of human alpha 1-antitrypsin causes a protein folding defect. Nat. Struct. Biol., 1995, 2(5), 363-367.
174. Sveger, T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr. Scand., 1988, 77(6), 847-851.
175. Bruce, D.; Perry, D.J.; Borg, J.Y.; Carrell, R.W.; Wardell, M.R. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp). J. Clin. Invest., 1994, 94(6), 2265-2274.
176. rd. A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J. Biol. Chem., 1993, 268(24), 18088-18094.
177. Crowther, D.C.; Serpell, L.C.; Dafforn, T.R.; Gooptu, B.; Lomas, D.A. Nucleation of alpha 1-antichymotrypsin polymerization. Biochemistry, 2003, 42(8), 2355-2363.
178. Kelly, E.; Greene, C.M.; Carroll, T.P.; McElvaney, N.G.; O'Neill, S.J. Selenoprotein S/SEPS1 modifies endoplasmic reticulum stress in Z variant {alpha}1-antitrypsin deficiency. J. Biol. Chem., 2009, 284(25), 16891-16897.
179. Bjork, I.; Nordling, K.; Larsson, I.; Olson, S.T. Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor. J. Biol. Chem., 1992, 267(27), 19047-19050.
180. Chang, W.S.; Wardell, M.R.; Lomas, D.A.; Carrell, R.W. Probing serpin reactive-loop conformations by proteolytic cleavage. Bio-chem. J., 1996, 314 (Pt 2), 647-653.
181. Fitton, H.L.; Pike, R.N.; Carrell, R.W.; Chang, W.S. Mechanisms of antithrombin polymerisation and heparin activation probed by the insertion of synthetic reactive loop peptides. Biol. Chem., 1997, 378(9), 1059-1063.
182. Schulze, A.J.; Baumann, U.; Knof, S.; Jaeger, E.; Huber, R.; Lau-rell, C.B. Structural transition of alpha 1-antitrypsin by a peptide sequentially similar to beta-strand s4A. Eur. J. Biochem., 1990, 194(1), 51-56.
183. Mahadeva, R.; Dafforn, T.R.; Carrell, R.W.; Lomas, D.A. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z al-pha(1)-antitrypsin-related cirrhosis. J. Biol. Chem., 2002, 277(9), 6771-6774.
184. Chowdhury, P.; Wang, W.; Lavender, S.; Bunagan, M.R.; Klemke, J.W.; Tang, J.; Saven, J. G.; Cooperman, B. S.; Gai, F. Fluorescence correlation spectroscopic study of serpin depolymerization by computationally designed peptides. J. Mol. Biol., 2007, 369(2), 462-473.
185. Chang, Y.P.; Mahadeva, R.; Chang, W.S.; Lin, S.C.; Chu, Y.H. Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization. J. Cell. Mol. Med., 2009, 13(8B), 2304-2316.
186. Mallya, M.; Phillips, R.L.; Saldanha, S.A.; Gooptu, B.; Brown, S.C.; Termine, D.J.; Shirvani, A. M.; Wu, Y.; Sifers, R. N.; Abag-yan, R.; Lomas, D. A. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J. Med. Chem., 2007, 50(22), 5357-5363.
187. Parfrey, H.; Dafforn, T.R.; Belorgey, D.; Lomas, D.A.; Mahadeva, R. Inhibiting polymerization: new therapeutic strategies for Z al-pha1-antitrypsin-related emphysema. Am. J. Respir. Cell. Mol. Biol., 2004, 31(2), 133-139.
188. Sato, S.; Ward, C.L.; Krouse, M.E.; Wine, J.J.; Kopito, R.R. Glyc-erol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem., 1996, 271(2), 635-638.
189. Chow, M.K.; Devlin, G.L.; Bottomley, S.P. Osmolytes as modulators of conformational changes in serpins. Biol. Chem., 2001, 382(11), 1593-1599.
190. Devlin, G.L.; Parfrey, H.; Tew, D.J.; Lomas, D.A.; Bottomley, S.P. Prevention of polymerization of M and Z alpha1-Antitrypsin (al-pha1-AT) with trimethylamine N-oxide. Implications for the treatment of alpha1-at deficiency. Am. J. Respir. Cell Mol. Biol., 2001, 24(6), 727-732.
191. Burrows, J.A.; Willis, L.K.; Perlmutter, D.H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. USA, 2000, 97(4), 1796-1801.
192. Zeitlin, P.L.; Diener-West, M.; Rubenstein, R.C.; Boyle, M.P.; Lee, C.K.; Brass-Ernst, L.; Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol. Ther., 2002, 6(1), 119-126.
193. Teckman, J.H. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J. Pediatr. Gastroenterol. Nutr., 2004, 39(1), 34-37.
194. Cantin, A.M.; Woods, D.E.; Cloutier, D.; Dufour, E.K.; Leduc, R. Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. Am. J. Respir. Cell Mol. Biol., 2002, 27(6), 659-665.
195. Kwon, K.S.; Song, M.; Yu, M.H. Purification and characterization of alpha 1-antitrypsin secreted by recombinant yeast Saccharomy-ces diastaticus. J. Biotechnol., 1995, 42(3), 191-195.
196. Kang, H.A.; Nam, S.W.; Kwon, K.S.; Chung, B.H.; Yu, M.H. High-level secretion of human alpha 1-antitrypsin from Saccharo-myces cerevisiae using inulinase signal sequence. J. Biotechnol., 1996, 48(1-2), 15-24.
197. Sandoval, C.; Curtis, H.; Congote, LF. Enhanced proliferative effects of a baculovirus-produced fusion protein of insulin-like growth factor and alpha(1)-proteinase inhibitor and improved anti-elastase activity of the inhibitor with glutamate at position 351. Protein Eng., 2002, 15(5), 413-418.
198. Massoud, M.; Bischoff, R.; Dalemans, W.; Pointu, H.; Attal, J.; Schultz, H.; Clesse, D.; Stinnakre, M. G.; Pavirani, A.; Houdebine, L. M. Expression of active recombinant human alpha 1-antitrypsin in transgenic rabbits. J. Biotechnol., 1991, 18(3), 193-203.
199. Archibald, A.L.; McClenaghan, M.; Hornsey, V.; Simons, J.P.; Clark, A.J. High-level expression of biologically active human alpha 1-antitrypsin in the milk of transgenic mice. Proc. Natl. Acad. Sci. USA, 1990, 87(13), 5178-5182.
200. Wright, G.; Carver, A.; Cottom, D.; Reeves, D.; Scott, A.; Simons, P.; Wilmut, I.; Garner, I.; Colman, A. High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Biotechnology (N Y), 1991, 9(9), 830-834.
201. Spencer, L.T.; Humphries, J.E.; Brantly, M.L. Antibody response to aerosolized transgenic human alpha1-antitrypsin. N. Engl. J. Med., 2005, 352(19), 2030-2031.
202. Kay, M.A.; Baley, P.; Rothenberg, S.; Leland, F.; Fleming, L.; Ponder, K.P.; Ponder, K. P.; Liu, T.; Finegold, M.; Darlington, G.; Pokorny, W.; Woo, S.L.C. Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced he-patocytes. Proc. Natl. Acad. Sci. USA, 1992, 89(1), 89-93.
203. [203] Morral, N.; Parks, R.J.; Zhou, H.; Langston, C.; Schiedner, G.; Quinones, J.; Graham, F. L.; Kochanek, S.; Beaudet, A. L. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum. Gene. Ther., 1998, 9(18), 2709-2716.
204. Canonico, A.E.; Conary, J.T.; Meyrick, B.O.; Brigham, K.L. Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits. Am. J. Respir. Cell Mol. Biol., 1994, 10(1), 24-29.
205. Song, S.; Goudy, K.; Campbell-Thompson, M.; Wasserfall, C.; Scott-Jorgensen, M.; Wang, J.; Tang, Q.; Crawford, J. M.; Ellis, T. M.; Atkinson, M. A.; Flotte, T. R. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene. Ther., 2004, 11(2), 181-186.
206. Lu, Y.; Choi, Y.K.; Campbell-Thompson, M.; Li, C.; Tang, Q.; Crawford, J.M.; Flotte, T. R.; Song, S. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J. Gene. Med., 2006, 8(6), 730-735.
207. Liqun Wang, R.; McLaughlin, T.; Cossette, T.; Tang, Q.; Foust, K.; Campbell-Thompson, M.; Martino, A.; Cruz, P.; Loiler, S.; Mueller, C.; Flotte, T. R. Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther., 2009, 17(1), 81-87.
208. Cruz, P.E.; Mueller, C.; Cossette, T.L.; Golant, A.; Tang, Q.; Beat-tie, S.G.; Brantly, M.; Campbell-Thompson, M.; Blomenkamp, K. S.; Teckman, J. H.; Flotte, T. R. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab. Invest., 2007, 87(9), 893-902.
209. Cutrona, G.; Carpaneto, E.M.; Ulivi, M.; Roncella, S.; Landt, O.; Ferrarini, M.; Boffa, L. C. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat. Biotechnol., 2000, 18(3), 300-303.
210. Nastruzzi, C.; Cortesi, R.; Esposito, E.; Gambari, R.; Borgatti, M.; Bianchi, N.; Feriotto, G.; Mischiati, C. Liposomes as carriers for DNA-PNA hybrids. J. Control. Release, 2000, 68(2), 237-249.
211. Luisetti, M.; Seersholm, N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax, 2004, 59(2), 164-169.